Videos

John Brandsema, MD, and Julie Parsons, MD, discuss considerations for combination SMA treatment and factors impacting SMA care pathways, such as prior authorization and multistep therapies.

In this final video of a three-part video series, Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, shares a key takeaway from Quest's recent Health Trends Survey. Results reveal how cancer diagnosis numbers are still lagging to pre-pandemic levels of 11%. Fesko adds that bringing cancer screenings to the community can increase diagnosis numbers, leading to care sooner.

Dr. Yuri Fesko of Quest Diagnostics says the "pathways approach" helped one health system speed the time between diagnosis and targeted treatment for lung cancer by as much as a month for some patients. This is the second part of a three-part video series.

Medical experts provide insights on factors impacting SMA treatment strategies.

Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, talks about why shortening this gap is critical to ensuring better patient outcomes and shared steps hospitals, health systems and physicians can take now to reduce testing delays, improve outcomes and lower costs of care. This is the first part of a three-part video series.

A lack of guidelines impair the management of Demodex blepharitis.

Disease-modifying treatments are highlighted as key contributors to the optimization of SMA management.

Medical experts illustrate characteristics in the presentation of lupus nephritis.

Douglas K. Devries, OD, discusses how Demodex blepharitis affects patients’ quality of life and associated financial burden.

Julie Parsons, M.D., and John Brandsema, M.D., explore economic burdens associated with SMA.

Disease-modifying agents play a significant role in treatment strategies for patients with SMA.

Douglas K. Devries, OD, outlines the common risk factors associated with Demodex blepharitis.

Julie Parsons, MD, and John Brandsema, MD, open a discussion surrounding prevalence of spinal muscular atrophy (SMA).

Douglas K Devries, OD, illustrates the current prevalence of patients diagnosed with Demodex blepharitis.

Dr Rosmarin navigates unmet needs and the trajectory of vitiligo treatment.

Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing and CMS value-based trends vs commercial payer trends. Chaet also addressed the status of select payment models like bundled and episodic, and more.

Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing and CMS value-based trends vs commercial payer trends.

Chester "Bernie" Good, senior medical director for the Center for Value Based Pharmacy Initiatives at UPMC Health Plan, gets in depth on value-based contracts and shares the results of the 2019 contract between UPMC and AstraZeneca for Brilinta. Good addressed value-based contracts last week at AMCP Nexus 2022 conference in National Harbor, Maryland.

Julie Kendle, Director, Clinical Pharmacy Director, Clinical Pharmacy at IPD Analytics addresses tips on improving accumulators and ways for PBMs or payers to make their accumulator and maximizer programs more acceptable to patients. Kendle spoke at this year's AMCP Nexus meeting in National Harbor, Maryland.

Payer perspectives are considered for the treatment of vitiligo.

Kelly Price, vice president of market access for Mahana Therapeutics, compared the difference between digital therapeutics, prescription digital therapeutics and how FDA approval factors into that difference. She also shared what's hopeful and what's to come as far as coverage decisions, rule changes and FDA guidance for digital therapeutics in 2023.

Yuqian Liu, Pharm.D., and Michelle Booth, Pharm.D., of Magellan Rx Management, discuss the background and consequences of step therapy in Medicare Part B in an interview prior to their session at the AMCP Nexus 2022 meeting in National Harbor, Maryland.

Kevin Astle, Pharm.D., discussed on-demand HIV preexposure prophylaxis (PrEP), the advent of long-term injectables, and updated CDC guidelines at the AMCP Nexus 2022 meeting in National Harbor, Maryland.

Samsung Bioepis executive Tom Newcomer’s touts the 10-year-old biosimilar company’s achievements as it gets ready to launch its Humira biosimilar, Hadlima.

Hadlima is scheduled to be on to the market in July 2023. In an interview with Managed Healthcare Executive®, a Samsung Bioepis executive says data on Hadlima’s interchangeability won’t be ready till 2024.

Dr Rosmarin describes the impacts of ruxolitinib on the treatment strategies for vitiligo.

Tom Newcomer, head of U.S. market access for the maker of Humira biosimilar Hadlima, deflected questions on price but touted the drug’s track record overseas.

Tom Newcomer, head of U.S. market access for Samsung Bioepis, maker of Hadlima, a Humira biosimilar, said some potential customers want to see which biosimilars will grab a large market share before deciding on which one to buy

Watts, chief emergency management medical officer, director of global health and a pediatric emergency medicine physician at Children’s Mercy Kansas City, is one of 10 winners in this year's Emerging Industry Leaders series.

With his closing thoughts, Kareem Karara looks to the potential pipeline biologic development of biosimilars and unbranded biologics.